Right. When I think about Argentina, for example--I'm not an expert in that area, so I'll add that caveat--if they have changed their method of approvals and have moved more to market acceptance criteria over and above the scientific criteria, they won't see an immediate shutdown. But they may see, over time, a lack of investment going in due to predictability of commercialization of the products going in there.
So it may not be immediate, but over time, longer term, I would see and expect that research and investment dollars would be somewhat spooked away from that kind of environment where you're not relying solely on science. You are opening it up to other subjective criteria, and investors and companies that invest in research may not be there in the longer term.